Loxo Oncology Inc. (Nasdaq: LOXO) will present initial clinical data for LOXO-292 at the International Association for the Study of Lung Cancer 18th World Conference on Lung Cancer on October 18, 2017. Shares of the biopharmaceutical leaped $11.48 to close at $86.59.
